intrommune_icon_500x500.png
Intrommune Therapeutics Completes Enrollment in the Phase 1 OMEGA Study for Peanut Allergy
October 26, 2022 09:35 ET | Intrommune Therapeutics
Observed only mild and transient adverse events, with no use of emergency epinephrine Observed 98.4% patient compliance to date with novel OMIT therapeutic modality Safely started patients on dose...
intrommune_icon_500x500.png
Intrommune Expands and Strengthens Senior Leadership Team
September 28, 2022 09:35 ET | Intrommune Therapeutics
Appointment of Stuart Loesch as President Leverages His Strong Leadership Abilities and Extensive Expertise in Allergy and Pharmaceutical Development Appointment of William Berger, MD, MBA as Head of...
MRW.png
Food Allergy Market [2022-2027] | Global Market Size, Share, Growth Rate, Company Profiles, Demand, Key Finding, Revenue & Gross Margin, Market Drivers, Opportunities, Challenges and Risks Factors Analysis | Market Reports World
June 22, 2022 09:43 ET | Market Reports World
Pune, June 22, 2022 (GLOBE NEWSWIRE) -- Global Food Allergy Market (2022-2027) research report offers an in-depth analysis of market size, share, drivers, restraints, and so on. Moreover, this...
intrommune_icon_500x500.png
Intrommune Announces Expanded Scope of Phase 1 OMEGA Study in Adults with Peanut Allergy
June 22, 2022 09:31 ET | Intrommune Therapeutics
Amendment to Extend Study Duration to 48 weeks New Maintenance Period Is Designed to Evaluate Safety of INT301 After Long-term Exposure NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Intrommune...
Logo.png
Global Food Allergy Pipeline Insight | Clinical Trials Evaluation Research Report 2022 by DelveInsight
June 20, 2022 12:00 ET | DelveInsight Business Research LLP
Las Vegas, USA, June 20, 2022 (GLOBE NEWSWIRE) -- Global Food Allergy Pipeline Insight | Clinical Trials Evaluation Research Report 2022 by DelveInsight  Food Allergy Pipeline constitutes 35+...
intrommune_icon_500x500.png
Intrommune Therapeutics Names Nandini Murthy as Head of Regulatory
June 01, 2022 13:33 ET | Intrommune Therapeutics
NEW YORK, June 01, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and...
Worldwide Allergy Immunotherapy Industry to 2028 - Increasing Approval of Allergy Immunotherapy by Regulatory Authorities are Driving Growth
April 28, 2022 07:23 ET | Research and Markets
Dublin, April 28, 2022 (GLOBE NEWSWIRE) -- The "Allergy Immunotherapy Market, by Treatment Type, by Allergy Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity...
Outlook on the Meal Kit Delivery Services Global Market to 2030: Online Segment Accounted for the Largest Revenue Share of More Than 63.2% in 2021
April 21, 2022 06:43 ET | Research and Markets
Dublin, April 21, 2022 (GLOBE NEWSWIRE) -- The "Meal Kit Delivery Services Market Size, Share & Trends Analysis Report by Offering (Heat & Eat, Cook & Eat), by Service (Single,...
intrommune_icon_500x500.png
INT301 Continues to Meet Safety Goals in Phase 1 OMEGA Study in Adults with Peanut Allergy While Reaching Phase 2 Target Maintenance Dose
April 06, 2022 08:30 ET | Intrommune Therapeutics
INT301 Met Safety Goals Across Eleven Dose Levels Patient Treatment Now Ongoing in Cohort 3 Intrommune Expands Study Scope to Explore MTD NEW YORK, April 06, 2022 (GLOBE NEWSWIRE) -- Intrommune...
New Report Finds Major Gaps in Child Care Policies for Food Allergy Nationwide
February 25, 2022 06:50 ET | Asthma and Allergy Foundation of America
Washington, D.C., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Today, the Asthma and Allergy Foundation of America (AAFA) and the Elijah-Alavi Foundation (EAF) released “Child Care Policies for Food Allergy:...